These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26084346)

  • 1. Symptomatic therapy in multiple sclerosis: Big pharma should do more--commentary.
    Hutchinson M
    Mult Scler; 2015 Jul; 21(8):982-3. PubMed ID: 26084346
    [No Abstract]   [Full Text] [Related]  

  • 2. Symptomatic therapy in multiple sclerosis: Big pharma should do more - NO.
    Hughes SE; Gray OM
    Mult Scler; 2015 Jul; 21(8):978-9. PubMed ID: 26084348
    [No Abstract]   [Full Text] [Related]  

  • 3. Symptomatic therapy in multiple sclerosis: Big pharma should do more-YES.
    Siva A; Kantarci O
    Mult Scler; 2015 Jul; 21(8):980-2. PubMed ID: 26084347
    [No Abstract]   [Full Text] [Related]  

  • 4. The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
    Giovannoni G; Baker D; Schmierer K
    Mult Scler Relat Disord; 2015 Jan; 4(1):3-5. PubMed ID: 25787047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy.
    Nat Rev Drug Discov; 2011 Jun; 10(6):404. PubMed ID: 21629281
    [No Abstract]   [Full Text] [Related]  

  • 6. Biogen, Serono squabble over MS market.
    Davidson S
    Nat Biotechnol; 2001 Aug; 19(8):696-7. PubMed ID: 11479543
    [No Abstract]   [Full Text] [Related]  

  • 7. Doug williams.
    Williams D; Mullard A
    Nat Rev Drug Discov; 2014 Dec; 13(12):880-1. PubMed ID: 25435210
    [No Abstract]   [Full Text] [Related]  

  • 8. Monstrous crowing.
    Nat Biotechnol; 2001 Aug; 19(8):693. PubMed ID: 11479541
    [No Abstract]   [Full Text] [Related]  

  • 9. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 10. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Tischner JR
    Neurology; 2015 Nov; 85(19):1727. PubMed ID: 26553943
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Rittenhouse BE
    Neurology; 2015 Nov; 85(19):1727-8. PubMed ID: 26866071
    [No Abstract]   [Full Text] [Related]  

  • 12. 27th Annual JPMorgan Healthcare Conference--Biogen Idec.
    Gale S
    IDrugs; 2009 Mar; 12(3):140-1. PubMed ID: 19333888
    [No Abstract]   [Full Text] [Related]  

  • 13. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B; Tremlett H
    Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
    [No Abstract]   [Full Text] [Related]  

  • 14. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The experts and Big Pharma, the minister and his guru].
    Nau JY
    Rev Med Suisse; 2009 Nov; 5(225):2298. PubMed ID: 19999321
    [No Abstract]   [Full Text] [Related]  

  • 16. Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: commentary.
    Hutchinson M
    Mult Scler; 2012 Sep; 18(9):1213-4. PubMed ID: 22936684
    [No Abstract]   [Full Text] [Related]  

  • 17. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
    Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
    Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why big pharma needs to learn the three 'R's.
    Bradley D
    Nat Rev Drug Discov; 2005 Jun; 4(6):446. PubMed ID: 15959947
    [No Abstract]   [Full Text] [Related]  

  • 19. Big pharma and the UK Government.
    Collier J
    Lancet; 2006 Jan; 367(9505):97-8. PubMed ID: 16413862
    [No Abstract]   [Full Text] [Related]  

  • 20. [Promising results with methylprednisolone in multiple sclerosis. Lack of patent rights makes drug industry less interested].
    Kling A; Dahlqvist R
    Lakartidningen; 2007 Jan 17-23; 104(3):128-30. PubMed ID: 17302117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.